MAPT and Alzheimer disease: It provides a unique opportunity to identify clinical and biological changes that occur in preclinical stages of AD (related to amyloid deposition +/− tau in the absence of symptoms) and factors that influence progression to a symptomatic stage of AD and, within this, to a stage of functional autonomy loss.